Compugen Stock

Compugen EBITDA Margin

Delisted·Jun 15, 2026

The EBITDA Margin of Compugen (CGEN) as of Jul 24, 2026 is 43.05 %. In the previous year, EBITDA Margin was -53.44 % — a change of -180.56% (higher).

EBITDA Margin

43.05 %

YoY

-180.56%

Last updated:

EBITDA Margin of Compugen is 2026 43.05 % . EBITDA Margin of Compugen was 2025 -53.44 % . It decreases by -180.56% higher compared to the previous year.
Access this data via the Eulerpool API

Compugen Stock analysis

What does Compugen do? Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv. Compugen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compugen stock

EBITDA Margin of Compugen is 43.05 % in 2026.

Access this data via the Eulerpool API

Margins — Compugen

All Key Metrics — Compugen